Could a common ED drug help fontan hearts? new trial aims to find out
NCT ID NCT05206955
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether tadalafil, a drug that relaxes blood vessels, can improve blood flow and protect organs in adults who had Fontan surgery for a single-ventricle heart defect. About 80 participants will receive either tadalafil or a placebo daily for a year. Researchers will measure changes in blood vessel function, liver stiffness, kidney function, and exercise capacity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tadalafil
- What this could lead to
- If it works, this could lead to a new treatment to improve blood flow and protect the liver, kidneys, and exercise ability in people living with Fontan circulation.
- What could go wrong
- This is a phase 3 trial, but tadalafil has not been proven effective for this condition before. It may not improve outcomes, and side effects like headache or muscle aches are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FONTAN PALLIATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States